Abstract
Marfan syndrome is a connective-tissue disease inherited in an autosomal dominant manner and caused mainly by mutations in the gene FBN1. This gene encodes fibrillin-1, a glycoprotein that is the main constituent of the microfibrils of the extracellular matrix. Most mutations are unique and affect a single amino acid of the protein. Reduced or abnormal fibrillin-1 leads to tissue weakness, increased transforming growth factor β signaling, loss of cell–matrix interactions, and, finally, to the different phenotypic manifestations of Marfan syndrome. Since the description of FBN1 as the gene affected in patients with this disorder, great advances have been made in the understanding of its pathogenesis. The development of several mouse models has also been crucial to our increased understanding of this disease, which is likely to change the treatment and the prognosis of patients in the coming years. Among the many different clinical manifestations of Marfan syndrome, cardiovascular involvement deserves special consideration, owing to its impact on prognosis. However, the diagnosis of patients with Marfan syndrome should be made according to Ghent criteria and requires a comprehensive clinical assessment of multiple organ systems. Genetic testing can be useful in the diagnosis of selected cases.
Key Points
-
Marfan syndrome is an autosomal-dominant connective-tissue disorder usually caused by mutations in the gene that encodes fibrillin-1
-
Fibrillin-1 is the major constituent of extracellular microfibrils and has structural and regulatory functions in the extracellular matrix
-
Marfan syndrome phenotype is thought to be the result of structural abnormalities and dysregulation of transforming growth factor β signaling
-
Marfan syndrome typically affects cardiovascular, skeletal, ocular, and neural systems and its diagnosis is based on clinical (Ghent) criteria
-
Aortic root dilatation in the leading cause of morbidity and mortality in patients with Marfan syndrome
-
Many connective-tissue disorders share phenotypic features with Marfan syndrome and should, therefore, be considered in the differential diagnosis
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marfan, A. Un cas de déformation congénitale des quatre membres, plus prononcée aux extrémités, caractérisée par l´allongement des os avec un certain degré d´amincissement [French]. Bull. Mem. Soc. Med. Hop (Paris) 13, 220–226 (1896).
De Paepe, A., Devereux, R. B., Dietz, H. C., Hennekam, R. C. & Pyeritz, R. E. Revised diagnostic criteria for the Marfan syndrome. Am. J. Med. Genet. 62, 417–426 (1996).
Cañadas, V., Vilacosta, I., Bruna, I. & Fuster, V. Marfan syndrome. Part 2: treatment and management of patients. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2010.31
Keane, M. G. & Pyeritz, R. E. Medical management of Marfan syndrome. Circulation 117, 2802–2813 (2008).
Pearson, G. D. et al. Report of the National Heart, Lung and Blood Institute and National Marfan Foundation Working Group on Research in Marfan Syndrome and Related Disorders. Circulation 1 18, 785–791 (2008).
Faivre, L. et al. Effect of mutation type and location on clinical outcome in 1013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am. J. Hum. Genet. 81, 454–466 (2007).
Williams, A., Davies, S., Stuart, A. G., Wilson, D. G. & Fraser, A. G. Medical treatment of Marfan syndrome: a time for change. Heart 94, 414–421 (2008).
Ammash, N. M., Sundt, T. M. & Connolly, H. M. Marfan syndrome—diagnosis and management. Curr. Probl. Cardiol. 33, 7–39 (2008).
Mizuguchi, T. & Matsumoto, N. Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J. Hum. Genet. 52, 1–12 (2007).
Boileau, C. et al. Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes. Am. J. Hum. Genet. 53, 46–54 (1993).
Collod, G. et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat. Genet. 8, 264–268 (1994).
Mizuguchi, T. et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat. Genet. 36, 855–860 (2004).
Dietz, H. et al. The question of heterogeneity in Marfan syndrome. Nat. Genet. 9, 228–231 (1995).
Loeys, B. L. et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37, 275–281 (2005).
Pannu, H. et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 112, 513–520 (2005).
Attias, D. et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 120, 2541–2549 (2009).
El-Hamamsy, I. & Yacoub, M. H. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat. Rev. Cardiol. 6, 771–786 (2009).
Gelb, B. D. Marfan's syndrome and related disorders: more tightly connected than we thought. N. Engl. J. Med. 3 55, 841–844 (2006).
Chaudhry, S. S. et al. Fibrillin-1 regulates the bioavailability of TGFbeta1. J. Cell Biol. 176, 355–367 (2007).
Schlatmann, T. J. & Becker, A. E. Pathogenesis of dissecting aneurysm of aorta. Comparative histopathologic study of significance of medial changes. Am. J. Cardiol. 39, 21–26 (1977).
Erdheim, J. Medionecrosis aortae idiopathica cystica [German]. Virchows Arch. 273, 454–479 (1929).
Dietz, H. et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics 17, 468–475 (1993).
Eldadah, Z. A., Brenn, T., Furthmayr, H. & Dietz, H. Expression of a mutant fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. J. Clin. Invest. 95, 874–880 (1995).
Judge, D. P. et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J. Clin. Invest. 114, 172–181 (2004).
Pereira, L. et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc. Natl Acad. Sci. USA 96, 3819–3823 (1999).
Neptune, E. R. et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407–411 (2003).
Ng, C. M. et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J. Clin. Invest. 114, 1586–1592 (2004).
Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117–121 (2006).
Nataatmadja, M., West, J. & West, M. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation 114, I371–I377 (2006).
Nagashima, H. et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 104, I282–I287 (2001).
Milewicz, D. M., Dietz, H. C. & Miller, D. C. Treatment of aortic disease in patients with Marfan syndrome. Circulation 111, e150–e157 (2005).
Lalchandani, S. & Wingfield, M. Pregnancy in women with Marfan's syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 110, 125–130 (2003).
Nollen, G. J. et al. Pulmonary artery root dilatation in Marfan syndrome: quantitative assessment of an unknown criterion. Heart 8 7, 470–471 (2002).
Judge, D. P. & Dietz, H. C. Marfan's syndrome. Lancet 366, 1965–1976 (2005).
Bhudia, S. K. et al. Mitral valve surgery in the adult Marfan syndrome patient. Ann. Thorac. Surg. 81, 843–848 (2006).
Savolainen, A. et al. Left ventricular function in children with the Marfan syndrome. Eur. Heart J. 1 5, 625–630 (1994).
Yetman, A. T., Bornemeier, R. A. & McCrindle, B. W. Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death? J. Am. Coll. Cardiol. 41, 329–332 (2003).
Chatrath, R., Beauchesne, L. M., Connolly, H. M., Michels, V. V. & Driscoll, D. J. Left ventricular function in the Marfan syndrome without significant valvular regurgitation. Am. J. Cardiol. 91, 914–916 (2003).
Beighton, P. et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. Am. J. Med. Genet. 29, 581–594 (1988).
Dean, J. C. Marfan syndrome: clinical diagnosis and management. Eur. J. Hum. Genet. 15, 724–733 (2007).
Lang, R. M. et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 18, 1440–1463 (2005).
Roman, M. J., Devereux, R. B., Kramer-Fox, R. & O'Loughlin, J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am. J. Cardiol. 64, 507–512 (1989).
Reed, C. M., Richey, P. A., Pulliam, D. A., Somes, G. W. & Alpert, B. S. Aortic dimensions in tall men and women. Am. J. Cardiol. 71, 608–610 (1993).
Mart, C. R., Khan, S. A., Smith, F. C. & Kavey, R. E. W. A new on-line method for predicting aortic root dilatation during two-dimensional echocardiography in pediatric patients with Marfan syndrome using the sinus of valsalva to annulus ratio. Pediatr. Cardiol. 24, 118–121 (2003).
Roman, M. J., Rosen, S. E., Kramer-Fox, R. & Devereux, R. B. Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J. Am. Coll. Cardiol. 22, 1470–1476 (1993).
Nemet, A. Y., Assia, E. I., Apple, D. J. & Barequet, I. S. Current concepts of ocular manifestations in Marfan syndrome. Surv. Ophthalmol. 51, 561–575 (2006).
Nelson, J. D. The Marfan syndrome, with special reference to congenital enlargement of the spinal canal. Br. J. Radiol. 31, 561–564 (1958).
Habermann, C. R. et al. MR evaluation of dural ectasia in Marfan syndrome: reassessment of the established criteria in children, adolescents, and young adults. Radiology 234, 535–541 (2005).
Oosterhof, T. et al. Quantitative assessment of dural ectasia as a marker for Marfan syndrome. Radiology 220, 514–518 (2001).
Boileau, C., Jondeau, G., Mizuguchi, T. & Matsumoto, N. Molecular genetics of Marfan syndrome. Curr. Opin. Cardiol. 20, 194–200 (2005).
Glesby, M. J. & Pyeritz, R. E. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 262, 523–528 (1989).
Loeys, B. L. et al. Aneurysm syndromes caused by mutations in the TGF-β receptor. N. Engl. J. Med. 355, 788–798 (2006).
Williams, J. A. et al. Early surgical experience with Loeys–Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease. Ann. Thorac. Surg. 83, S757–S763 (2007).
Pannu, H., Tran-Fadulu, V. & Milewicz, D. M. Genetic basis of thoracic aortic aneurysms and aortic dissections. Am. J. Med. Genet. C Semin. Med. Genet. 139C, 10–16 (2005).
Guo, D. C. et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat. Genet. 39, 1488–1493 (2007).
Zhu, L. et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat. Genet. 38, 343–349 (2006).
Callewaert, B. L. et al. Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: report of 14 novel mutations and review of the literature. Hum. Mutat. 30, 334–341 (2009).
Ades, L. C. et al. FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited. Am. J. Med. Genet. A 140, 1047–1058 (2006).
Callewaert, B. L. et al. Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families. Hum. Mutat. 29, 150–158 (2008).
Franceschini, P., Guala, A., Licata, D., Di Cara, G. & Franceschini, D. Arterial tortuosity syndrome. Am. J. Med. Genet. 91, 141–143 (2000).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cañadas, V., Vilacosta, I., Bruna, I. et al. Marfan syndrome. Part 1: pathophysiology and diagnosis. Nat Rev Cardiol 7, 256–265 (2010). https://doi.org/10.1038/nrcardio.2010.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.30
This article is cited by
-
Temporomandibular disorders in individuals with Marfan syndrome: an exploratory analysis
Head & Face Medicine (2024)
-
Application of single-sperm sequencing in a male with Marfan syndrome: a case report and a literature review
Journal of Genetics (2021)
-
Non-aortic cardiovascular disease in Marfan syndrome: a nationwide epidemiological study
Clinical Research in Cardiology (2021)
-
Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO
Nature Communications (2021)
-
Characterization of doxycycline-mediated inhibition of Marfan syndrome-associated aortic dilation by multiphoton microscopy
Scientific Reports (2020)